The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma.
- Author:
Shu WANG
1
;
Jia-qing ZHANG
;
Xin-min QIAO
;
De-qi YANG
;
Fu-zhong TONG
;
Hong-jun LIU
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Breast Neoplasms; drug therapy; metabolism; Chemotherapy, Adjuvant; Epirubicin; administration & dosage; Female; Follow-Up Studies; Humans; Immunohistochemistry; Neoadjuvant Therapy; Paclitaxel; administration & dosage; Receptors, Estrogen; biosynthesis; Receptors, Progesterone; biosynthesis
- From: Chinese Journal of Surgery 2005;43(15):1011-1013
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of neoadjuvant chemotherapy on estrogen receptor (ER) and progesterone receptor (PR) expression in breast carcinoma.
METHODSSamples were obtained from 31 patients with breast carcinoma who received neo-adjuvant chemotherapy, ER or PR expressions were analyzed in preoperative core biopsies and final surgical specimens.
RESULTSER level was up-regulated in 13 (41.9%) out of 31 cases, PR level was up-regulated in 10 (32.3%). Both ER level and PR level were up-regulated in 8 (25.8%) out of 31 cases.
CONCLUSIONSNeoadjuvant chemotherapy may impact the hormone receptor status, ER and PR expression re-analysis in final surgical specimens is recommended.
